Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Inclusion Criteria:

• Be able and willing to provide written informed consent.
• 18 to 75 years old.
• Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Has a histologically confirmed diagnosis of Gastric or Gastroesophageal JunctionAdenocarcinoma(G/GEJ).
• Has Stage T3-4N+M0 G/GEJ (American Joint Committee on Cancer [AJCC])
• Has measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
• Has adequate organ function.

Exclusion Criteria:

• Are there suspected metastases or locally advanced, unresectable disease, regardlessof disease stage.
• Is currently participating in a study of an investigational agent or using aninvestigational device.
• Has undergone major surgery within 30 days of Study Day 1.
• Has an active autoimmune disease that has required systemic treatment in the past 2years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressivedrugs).
• Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).
• History of myocardial infarction, unstable angina, congestive heart failure within 12months prior to day 1 of study treatment.
• Has known psychiatric or substance abuse disorders that would interfere withcooperation with the requirements of the study.
• Has received a live virus vaccine within 30 days of the planned first dose of studytherapy.